GVAG
CATX icon

Great Valley Advisor Group’s Perspective Therapeutics CATX Stock Holding History

Great Valley Advisor Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,200
Closed -$14.3K – 783
2024
Q1 		$14.3K Hold
1,200
– – ﹤0.01% 747
2023
Q4 		$4.82K Hold
1,200
– – ﹤0.01% 710
2023
Q3 		$3.28K Hold
1,200
– – ﹤0.01% 675
2023
Q2 		$8.02K Hold
1,200
– – ﹤0.01% 700
2023
Q1 		$7.66K Hold
1,200
– – ﹤0.01% 694
2022
Q4 		$2.96K Hold
1,200
– – ﹤0.01% 696
2022
Q3 		$3K Hold
1,200
– – ﹤0.01% 672
2022
Q2 		$4K Buy
+1,200
New +$3.67K ﹤0.01% 672

Other funds holding CATX

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Great Valley Advisor Group's CATX Position: Q2 2024 in Review

Great Valley Advisor Group sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 1,200 shares — an estimated $14.3K sold.

Great Valley Advisor Group first reported a position in CATX in Q2 2022 and held it in 8 quarters. The position peaked at $14.3K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Great Valley Advisor Group reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Great Valley Advisor Group sold 1,200 Perspective Therapeutics shares in Q2 2024, an estimated $14.3K.
  • Great Valley Advisor Group first reported a position in Perspective Therapeutics in Q2 2022 and held it in 8 quarters.
  • Great Valley Advisor Group's Perspective Therapeutics position peaked at $14.3K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Great Valley Advisor Group's 13F filing for Q2 2024, filed 16 Jul 2024.